Key takeaways What are compounded GLP-1 medications? Quick answer: Compounded GLP-1s are pharmacy-made versions of semaglutide or tirzepatide, prescribed for individual patients by a licensed clinician. They use the same active ingredient as Wegovy, Ozempic, or Zepbound but are not FDA-approved as finished products. Compounded GLP-1s cost $96-$300 per month compared to $349-$1,500 for brand-name […]
By Astra Editorial Team
Published:
Updated:
Quick answer: Compounded GLP-1s are pharmacy-made versions of semaglutide or tirzepatide, prescribed for individual patients by a licensed clinician. They use the same active ingredient as Wegovy, Ozempic, or Zepbound but are not FDA-approved as finished products. Compounded GLP-1s cost $96-$300 per month compared to $349-$1,500 for brand-name versions.
A compounded GLP-1 is a version of semaglutide or tirzepatide that a pharmacy makes for you, based on a prescription from a licensed clinician. The pharmacy prepares the active ingredient in an injectable form (sometimes with an additive like vitamin B12) and ships it to you.
The active ingredient is the same one you would find in Wegovy, Ozempic, or Zepbound. The finished vial is not FDA-approved because a compounding pharmacy made it, not Novo Nordisk or Eli Lilly.
Federal law lets compounding pharmacies copy drugs that are in shortage, which is how compounded semaglutide became a mainstream option in 2022 when Ozempic and Wegovy ran out. The shortage is now over and the rules have changed, but 503A compounding for individual patients is still going on under a narrower framework covered below.
Quick answer: Compounded GLP-1s are made under federal compounding laws (Section 503A and 503B of the FD&C Act), which let licensed pharmacies prepare custom medications for patients with specific clinical needs. Most compounded GLP-1s come from 503A pharmacies regulated by state pharmacy boards.
Compounding has been around for decades as a regulated pharmacy practice under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. It exists for patients allergic to an ingredient in an approved drug, patients who need a dose that doesn’t come pre-made, patients who can’t swallow a pill and need a liquid version, etc.
There are two kinds of compounding pharmacies:
Most compounded GLP-1s available through telehealth come from 503A pharmacies, while a smaller number comes from 503B facilities.
There are no FDA-approved generics of Wegovy, Ozempic, or Zepbound yet. Novo Nordisk’s main semaglutide patent doesn’t expire until 2032, and Eli Lilly’s tirzepatide patents run through at least 2036. A generic drug goes through its own FDA approval process where the agency reviews it, confirms it works the same way as the brand-name version, and approves it for sale.
A compounded drug is different. A pharmacy prepares it for one patient at a time based on a prescription. The active ingredient can be the same as what’s in the brand-name drug, but the finished compounded product itself hasn’t been through FDA approval.
So when you see “cheaper semaglutide” or “generic Ozempic” advertised online, it’s almost always compounded, not generic.
| Compounded GLP-1 | Brand-name GLP-1 | |
|---|---|---|
| Active ingredient | Semaglutide or tirzepatide | Semaglutide or tirzepatide |
| Finished product FDA-approved? | No | Yes |
| Made by | Licensed 503A or 503B compounding pharmacies | Novo Nordisk (semaglutide) or Eli Lilly (tirzepatide) |
| Delivery format | Vials (drawn into syringe) | Pre-filled injection pens |
| Standardized dosing | Varies by pharmacy | Built-in, click-to-dose |
| Self-pay cost per month | Semaglutide: $96-$300 Tirzepatide: $125-$400 | Wegovy: $349-$1,500 Zepbound: $349-$1,300Ozempic: $499-$1,200 |
Quick answer: The active ingredient works the same way. Everything around the molecule (inactive ingredients, dosing accuracy, storage, manufacturing quality) can vary by pharmacy, which is why choosing a legitimate 503A pharmacy matters.
The way a GLP-1 drug works in your body (slowing gastric emptying, helping with insulin response, telling your brain you’re full) does not depend on who prepared the medication. What varies is everything around the molecule: the inactive ingredients, how it’s prepared, how accurately it’s dosed, how it’s stored.
Two pens of brand-name Ozempic from any pharmacy work the same because the manufacturing is standardized. Two vials labeled “compounded semaglutide 2.5mg/mL” from two different pharmacies can perform differently, because the standard-setting is happening at the pharmacy level, not the manufacturer level.
When the pharmacy takes standardization seriously — PCAB accreditation, USP 797 sterile compounding, pharmaceutical-grade active ingredient from an FDA-registered source, consistent concentration across shipments — the finished product performs consistently.
Coverage, dose needs, tolerability, budget. A quick profile helps a licensed clinician tell you which path actually makes sense for your situation.
Take the assessment →Quick answer: The active ingredients (semaglutide and tirzepatide) are FDA-approved. The finished compounded products are not. This is a normal feature of compounded medications, but it does mean the pharmacy itself is doing the quality assurance that the FDA would otherwise do for a commercial product.
The FDA has reviewed semaglutide and tirzepatide as molecules and approved them in specific commercial products (Wegovy, Ozempic, Zepbound, Mounjaro) made under strict manufacturing rules. Compounded versions use the same molecule under a different regulatory framework: one built for per-patient preparation rather than mass production.
The FDA’s own language is that compounded drugs “have not undergone FDA premarket review for safety, effectiveness, and quality.” What it means in practice is that the pharmacy has to hold the quality line, and the standards it holds itself to (accreditation, USP compliance, ingredient sourcing) are what protect the patient.
The FDA-approved versions of semaglutide (Ozempic, Wegovy, Rybelsus) contain semaglutide base. Some compounding pharmacies use semaglutide salts instead, most commonly semaglutide sodium or semaglutide acetate.
The FDA has said salt forms are different active ingredients from the base and have NOT been evaluated for safety and effectiveness the same way. A compounded product made with a salt form is on weaker legal and clinical ground than one made with the base.
If you’re evaluating a provider, check that they use base, not salt.
Some compounders add vitamin B12 (or B6, niacinamide, glycine, carnitine) to semaglutide or tirzepatide. There’s no established weight-loss or diabetes benefit for these additions. They were really mostly added so the compounder could argue the finished product was not a copy of the brand-name drug.
A 2026 study in Expert Opinion on Drug Safety found that when tirzepatide is compounded with B12, the two can chemically bond into a molecule that isn’t present in FDA-approved tirzepatide. Eli Lilly replicated the finding and issued a public warning that the clinical effects of the new molecule are not known.
A straightforward compounded semaglutide or tirzepatide from a well-run pharmacy is a different product from a “personalized blend” with unnecessary additives. If a provider is offering combinations, ask why, and what stability testing supports the formulation.
Quick answer: Compounded semaglutide costs $96-$300 per month, and compounded tirzepatide runs $125-$400 per month. Brand-name GLP-1s run $349-$1,500 per month at retail, although Novo Nordisk and Eli Lilly both offer direct-to-consumer cash pricing that brings the floor down. For most uninsured patients, compounded is still the most affordable ongoing option.
Compounded semaglutide costs $96 to $300 per month depending on the provider, dose, and plan length. Lower-dose protocols and longer commitments push the price down; monthly plans without commitment sit at the top of the range.
Compounded tirzepatide runs $125 to $400 per month with the same dynamics. Annual plans on the most competitive platforms reach the bottom of the range; month-to-month plans without commitment sit at the top.
Manufacturer cash-pay programs have narrowed the gap in the last year. If you have insurance coverage for brand-name GLP-1s, your patient-pay cost can drop well below any of these numbers.
Only about 1 in 5 large employer plans covers GLP-1s specifically for weight loss as of 2025. For everyone else, compounded is often what makes ongoing treatment affordable. GLP-1s tend to lose effect if you stop them, so a $300/month plan you can actually maintain beats a $1,000/month plan you have to abandon after three months.
If your plan won’t cover Wegovy or Zepbound and manufacturer cash pricing is still out of reach, compounded semaglutide from a licensed 503A pharmacy starts at $96/month — with a clinician reviewing your case first.
See if compounded is right for you →Quick answer: Yes. 503A pharmacies can still legally compound semaglutide and tirzepatide for individual patients when the prescriber can document that the compounded product provides a significant difference for that patient compared to the FDA-approved version. That’s the framework Astra (try-astra.com) and other reputable telehealth providers operate under.
FDA adds semaglutide products (Ozempic, Wegovy) to the drug shortage list, making compounding legal.
Tirzepatide joins the shortage list, and compounded tirzepatide follows.
FDA declares the tirzepatide shortage resolved on December 19, 2024. Compounders sue, and the FDA stands by the decision.
FDA declares the semaglutide shortage resolved on February 21, 2025. Pharmacies get 60-90 days to wind down “essentially a copy” compounding.
Courts deny compounders’ preliminary injunctions (tirzepatide in March, semaglutide in April) clearing the way for FDA enforcement.
FDA clarifies the new rules. 503A pharmacies can still compound for individual patients when the prescription reflects a documented clinical reason, and the “essentially a copy” rule gets stricter.
FDA proposes to remove semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, which would stop 503B outsourcing facilities from compounding these drugs in bulk. Patient-specific 503A compounding is not affected.
FDA sends 25 more warning letters to telehealth companies for false or misleading claims about compounded GLP-1s, on top of ~30 letters issued in March 2026.
FDA extends the public comment period on the 503B Bulks List proposal to July 30, 2026. A final decision is expected later in 2026.
The April 1 update confirmed that 503A pharmacies can keep compounding GLP-1s for individual patients. The prescription has to reflect a real, patient-specific clinical rationale, meaning that the compounded product must provide “a significant difference” for that patient compared to the approved version.
Second, it cracked down on the “essentially a copy” workaround. Some compounders had been adding vitamin B12 to semaglutide to claim the result wasn’t a copy of Ozempic. The FDA pushed back: if the strengths are within 10% of the commercial drug and the route of administration is the same, it still counts as a copy.
In practice, this means a legitimate telehealth provider running through a real 503A pharmacy is on solid ground.
The 503B bulks list is the FDA-maintained list of ingredients that outsourcing facilities can compound in bulk without individual prescriptions. The FDA wants to remove semaglutide, tirzepatide, and liraglutide from that list. If this goes through, 503B bulk compounding of GLP-1s mostly stops, while 503A compounding with individual prescriptions keeps going.
Public comment now closes July 30, 2026, and a final decision is expected later in the year.
Astra (try-astra.com) works with VialsRx, a 503A pharmacy. Most reputable platforms will tell you what type of pharmacy fills their prescriptions if you ask. If yours won’t, that tells you something.
Quick answer: Yes, compounded GLP-1s can be safely used when a reputable pharmacy prepares them and a real clinical team supervises the treatment. FDA data shows meaningfully higher rates of preparation and dosing problems in the compounded market as a whole, but that’s because the market includes a lot of low-quality operators. Working with a rigorous provider changes that considerably.
Compounded GLP-1s are widely used. A July 2026 Gallup poll found that 11% of adults in the US now take a GLP-1 medication for weight loss (up from 3% in 2024), and roughly 19% of current users are on compounded or custom-mixed versions.
About a third of those compounded users switched from a brand-name product, and two-thirds of the switchers cited cost or insurance coverage as the reason. In other words, millions of people are using compounded GLP-1s safely and successfully.
Alongside that growth, safety reports have climbed. Poison control centers across the country have seen a more than 15-fold increase in calls related to injected weight-loss drugs since 2019, most tied to dosing errors that are more common with vial-and-syringe formats than with pre-filled pens. That’s why provider quality is the most important variable in whether compounded works out for you.
A 2026 pharmacovigilance study in Expert Opinion on Drug Safety analyzed FDA adverse event reports for GLP-1 receptor agonists and compared compounded versions with brand-name.
Reported side effects from the drug were only modestly higher in compounded users (nausea 1.27x, diarrhea 1.59x, abdominal pain 2.84x), which fits with the fact that it’s the same active ingredient. What stood out were reports tied to how the product was prepared and administered: 48.92x more reports of preparation errors, 19x more reports of contamination, and 8.51x more reports of manufacturing issues.
Those numbers describe the full compounded market, including operators using research-grade active ingredients, unclear labeling, and no meaningful clinical support. A patient working with a PCAB-accredited 503A pharmacy, USP 797 sterile compounding, pharmaceutical-grade ingredient from an FDA-registered source, and a clinician who actually reviews their case is not the average data point in that dataset.
Choosing the right operator is what moves you out of the risky pool.
The pharmacy behind your prescription is what separates a good outcome from a bad one. Astra runs on the checks that matter:
Brand-name GLP-1s come in pens. You just click to your dose and inject. Compounded GLP-1s come in vials, and you draw the dose into a syringe yourself.
This works fine when everything is set up well: clear written instructions, demo videos, the exact right syringes for your prescribed dose, one consistent concentration so the math doesn’t change between shipments. It fails when the pharmacy sends a vial with a generic instruction sheet and hopes for the best.
The FDA has documented cases where patients accidentally injected 10 to 20 times their prescribed dose because the setup left too much room for error. Those cases are almost always avoidable. A well-run provider closes the loop: right syringe, unambiguous instructions, ongoing clinical support if you have questions.
Astra (try-astra.com) works with VialsRx, a US-licensed 503A pharmacy, and a licensed clinician at Wasef Health, PC reviews every prescription. You get clear dosing instructions, the right syringes for your prescribed dose, a consistent concentration across shipments, and ongoing clinical support throughout treatment.
Here’s what separates a well-run pharmacy from a bad one, and what to look for whoever you choose:
Quick answer: Compounded GLP-1 is a good fit if your insurance doesn’t cover brand-name GLP-1s, if you need a dose or protocol the manufacturer doesn’t offer, or if the ongoing cost of brand-name would force you to stop treatment early. Brand-name is usually the better fit if your insurance covers it or you’re comfortable with the manufacturer cash price.
Compounded GLP-1 is often the right fit if:
Brand-name GLP-1 is probably the better fit if:
GLP-1 medications (compounded or brand-name) are not recommended for people with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome. They’re also not recommended during pregnancy, and people with severe gastrointestinal conditions like gastroparesis should talk to their doctor before starting.
Compounded GLP-1 medications are only available through telehealth platforms that work with licensed compounding pharmacies and prescribing clinicians. You can’t buy them without a prescription or over the counter. The most important decision, therefore, is the provider and the pharmacy behind it.
A 5-minute health profile is the starting point at Astra, where a licensed clinician at Wasef Health, PC reviews your case and decides whether compounded GLP-1, brand-name GLP-1, or something else fits your situation.
Compounded prescriptions are filled by VialsRx, a US-licensed 503A pharmacy. Microdose protocols start at $89 per month, and compounded semaglutide starts at $96 per month on the 3-month starter plan. No hidden fees. Cancel anytime.
Astra pairs licensed clinicians at Wasef Health, PC with a US-licensed 503A pharmacy, so what shows up at your door is what your clinician actually prescribed.
Start your health profile Takes about 5 minutes.Compounded semaglutide and Ozempic both contain the semaglutide molecule, but only Ozempic is FDA-approved as a finished product. Ozempic is manufactured by Novo Nordisk under Current Good Manufacturing Practice regulations. Compounded semaglutide is prepared per-prescription by a compounding pharmacy. The medication works through the same biological mechanism; the regulatory and manufacturing frameworks are different.
Compounded GLP-1s contain the same active ingredient as brand-name versions and can produce comparable results when prepared correctly by a reputable pharmacy at an appropriate dose. Consistency of results depends on the pharmacy and provider.
Compounded GLP-1 medications require a prescription and are only available through telehealth platforms that partner with licensed 503A pharmacies (or, less commonly, 503B facilities). Stay away from any source selling compounded semaglutide or tirzepatide without a prescription.
Yes. The transition involves matching your current compounded dose to a brand-name equivalent, with your clinician adjusting as needed. Because compounded doses aren’t always labeled the same way as brand-name doses, most clinicians will start you at a lower dose than the compounded amount you reported and titrate up from there.
If your insurance covers brand-name GLP-1s, your provider can help submit a prior authorization. If not, NovoCare and LillyDirect can bring brand-name pricing closer to compounded. Switching usually doesn’t mean pausing treatment in between.
This article is for educational purposes only and does not constitute medical advice. Consult a licensed physician regarding any medical condition or treatment.